Alnylam CEO John Maraganore said he was taken by surprise by Tekmira's suit. He said he learned of it in an email from his counterpart at Tekmira, Mark Murray, only minutes before the latter's press release.
Maraganore characterizes the whole thing as a complete surprise -- contrary to Tekmira's position that they had complained about the issue without receiving a response or satisfaction on their concerns. Maraganore said that doesn't represent Alnylam's point of view.
"I don’t think it’s a good strategy when you have a partnership. It’s certainly not a good strategy when you have a partner that has done as much funding as we have in the past, and frankly, has been there to support them for many, many years. It’s not what I would call the best example of relationship management I’ve ever seen.", said Maraganore, and he continued, " It seems to me this is a very misguided approach. The focus should be on clinical progress and science, and frankly, receiving their milestones and royalties." See Xconomy Boston.
Posted by Bruce Lehr March 19th 2011.